CSDX Stock — CS Diagnostics Corp.

CS Diagnostics Corp. (CSDX)

Updated October 9, 2026.

CSDX is a Stock. Its deepest 1-year drawdown was 99.9%.

CS Diagnostics Corp. designs, manufactures, and sells wellness and medical products, including MEDUSA, a surface disinfectant protection product, and CS-Protect Hydrogel, a medical device used in radiation therapy, serving markets in Germany and internationally. The company does not currently distribute dividends to shareholders. This equity stock may appeal to investors seeking exposure to medical device and wellness product companies rather than income-focused investors.

CSDX performance

Returns are updating. CSDX's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 99.9%.

CSDX key facts

Asset type

Stock

Asset class

Equity

Inception date

02/17/2005

Distribution frequency

None

Last close

$0.0004 (stale; as of 2026-10-09)

Market cap

$99,997

Average volume

4000.0

Payout ratio

0.0%

EPS

$0.00

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CSDX risks and drawbacks

The deepest 1-year drawdown on record here is 99.9%.

Who may consider CSDX — and who may not

It is a weaker fit for investors who need monthly cash flow (CSDX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on CSDX

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions